Uterine Sarcoma and Carcinosarcoma: A Two-Center Experience in Iran

Background: Uterine sarcomas (US) represent a rare and heterogeneous spectrum of tumors characterized by diverse clinical behaviors and tumor responses. This study aims to assess patient and tumor characteristics and oncologic outcomes.Method: This historical cohort study encompassed all patients with histologically confirmed diagnoses of the US who were referred to two oncology centers affiliated with Mashhad University of Medical Sciences (Iran) between March ۲۰۱۱ and April ۲۰۲۰. Data analyses were conducted using STATA version ۱۴.۰۲. Survival estimation was carried out utilizing the Kaplan-Meier method. The significance level was established at ۰.۰۵.Results: A total of ۳۳ patients were included in this study, comprising ۲۳ with US and ۱۰ with carcinosarcoma (CS). The mean age was ۴۹.۳ years for CS and ۶۲.۴ years for US (P = ۰.۰۰۰۱). Nearly all patients were overweight, with a mean body mass index of ۲۷.۱ (confidence interval: ۲۵.۶-۲۸.۷). The majority of patients were diagnosed at an early stage. The Federation of Gynecology and Obstetrics (FIGO) stage, patient's anemia, and surgical resection were identified as significant prognostic factors. The median overall survival was ۵۰.۸۸ ± ۵.۷ months. The survival rates at ۲, ۳, and ۵ years were ۷۵%, ۵۶%, and ۴۱%, respectively. No significant difference was observed between CS and US regarding overall and disease-free survival.Conclusion: Despite the typical early-stage diagnosis for US patients, the ۵-year survival rate remains low. This study underscores the pivotal role of FIGO stage, tumor size, and surgical resection as vital prognostic factors for survival.

کلیدواژه ها:

Uterine Neoplasms ، Carcinosarcoma ، Survival analysis ، Prognosis